We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 386% above its sector, the market expects faster growth.
Guangzhou Kingmed Diagnostics Group Co., Ltd. operates as a prominent independent medical laboratory provider. Its extensive service portfolio encompasses a wide array of offerings, such as medical diagnostic information, clinical trial assistance, and comprehensive laboratory services. The company also specializes in food and hygiene testing, health management solutions, and medical cold chain logistics. Additionally, Kingmed engages in scientific research, develops in vitro diagnostics, and utilizes advanced capabilities in healthcare big data, artificial intelligence, and forensic testing. Operating a network of 37 state-of-the-art testing facilities, the company maintains a significant presence across both mainland China and Hong Kong. Established in 2003, its corporate headquarters are situated in Guangzhou, China.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 603882.SS and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
